高尿酸血症治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Hyperuricemia - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0953
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年3月31日
◆ページ数:82
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Hyperuricemia – Pipeline Review, H1 2020
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Hyperuricemia – Pipeline Review, H1 2020, provides an overview of the Hyperuricemia (Metabolic Disorders) pipeline landscape.

High uric acid level, or hyperuricemia, is an excess of uric acid in blood. Symptoms include joints become swollen, tender and red, fever, chills, fatigue and kidney problems (caused by formation of kidney stones), or problems with urination. Predisposing factors include age, family history and certain medications. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid medications.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Hyperuricemia – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Hyperuricemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hyperuricemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperuricemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 6, 6, 1 and 6 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Hyperuricemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hyperuricemia (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Hyperuricemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hyperuricemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hyperuricemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hyperuricemia (Metabolic Disorders)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hyperuricemia (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hyperuricemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hyperuricemia – Overview
Hyperuricemia – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Hyperuricemia – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hyperuricemia – Companies Involved in Therapeutics Development
Allena Pharmaceuticals Inc
Arthrosi Therapeutics Inc
AstraZeneca Plc
FortuneRock (China) Ltd
Hinova Pharmaceuticals Inc
J-Pharma Co Ltd
Jiangsu Atom Bioscience and Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Nippon Chemiphar Co Ltd
NuBioPharma LLC
PegBio Co Ltd
Polaris Pharmaceuticals Inc
Shanghai Yingli Pharmaceutical Co Ltd
Suzhou Sinovent Pharmaceuticals Co Ltd
Teijin Pharma Ltd
Xiuzheng Pharmaceutical Group Co Ltd
Hyperuricemia – Drug Profiles
ABP-671 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ALLN-346 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
allopurinol – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AR-882 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
febuxostat – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HP-501 SR – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JPH-367 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NC-2500 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NC-2700 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PB-348 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pegadricase – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Urate Oxidase Replacement for Acute Hyperuricemia – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SFR-9350 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHR-4640 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Xanthine Oxidase for Gout and Hyperuricemia – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Xanthine Oxidase for Hyperuricemia – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Xanthine Oxidase for Hyperuricemia – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TEI-A – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TMX-049 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
verinurad – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XNW-3009 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YL-90148 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hyperuricemia – Dormant Projects
Hyperuricemia – Discontinued Products
Hyperuricemia – Product Development Milestones
Featured News & Press Releases
Oct 30, 2019: AstraZeneca to present pivotal roxadustat phase II data at the American Society of Nephrology Kidney Week 2019
Oct 17, 2019: Allena Pharmaceuticals to present new data on ALLN-346 at upcoming ACR/ARP Annual Meeting
Jul 17, 2019: Febuxostat (Adenuric): increased risk of cardiovascular death and all-cause mortality in clinical trial in patients with a history of major cardiovascular disease
Jun 21, 2019: FDA Joint Committee recommends approval of Uloric (Febuxostat)
Jun 13, 2019: Verinurad with febuxostat significantly reduces albuminuria and hyperuricaemia in patients with type ii diabetes in phase iia trial
Jan 11, 2019: Takeda Announces Outcome of FDA Advisory Committee Meeting to Review Uloric (febuxostat) Cardiovascular Outcomes Trial Results
Nov 01, 2018: Selecta Biosciences to provide update on SEL-212 development strategy, including planned head-to-head study versus Krystexxa
Oct 22, 2018: Allena Pharmaceuticals presents preclinical data demonstrating normalized urine uric acid excretion and plasma urate reduction following treatment with ALLN-346
Oct 18, 2018: Allena Pharmaceuticals to present data on Kidney Disease drug candidate ALLN-346 at ACR/ARHP 2018 Annual Meeting
Jun 19, 2018: Allena Pharmaceuticals Completes Animal Proof-of-Concept Study for ALLN-346, Lead Product Candidate for Hyperuricemia in the Setting of Advanced Chronic Kidney Disease
Jun 08, 2018: Selecta Biosciences to Present Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at EULAR 2018
Nov 29, 2017: Nippon Chemiphar Announces Progress on Its Hyperuricemia/Gout Projects; NC-2500 Shows Favorable Profile to Lower Serum Uric Acid in Phase-1 Study
Apr 21, 2017: Mylan Receives CHMP Positive Opinion For Febuxostat
Dec 07, 2016: Selecta Presents Phase 1 Clinical Data for Lead Product Candidate, SEL-212, in Patients with Hyperuricemia at 11th Annual IMVAC Summit
Jun 15, 2016: Scottish Medicines Consortium Accepts Adenuric (Febuxostat) for the Prevention and Treatment of Hyperuricaemia and Predicts Savings for NHS Scotland
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Hyperuricemia, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Hyperuricemia - Pipeline by Allena Pharmaceuticals Inc, H1 2020
Hyperuricemia - Pipeline by Arthrosi Therapeutics Inc, H1 2020
Hyperuricemia - Pipeline by AstraZeneca Plc, H1 2020
Hyperuricemia - Pipeline by FortuneRock (China) Ltd, H1 2020
Hyperuricemia - Pipeline by Hinova Pharmaceuticals Inc, H1 2020
Hyperuricemia - Pipeline by J-Pharma Co Ltd, H1 2020
Hyperuricemia - Pipeline by Jiangsu Atom Bioscience and Pharmaceutical Co Ltd, H1 2020
Hyperuricemia - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2020
Hyperuricemia - Pipeline by Nippon Chemiphar Co Ltd, H1 2020
Hyperuricemia - Pipeline by NuBioPharma LLC, H1 2020
Hyperuricemia - Pipeline by PegBio Co Ltd, H1 2020
Hyperuricemia - Pipeline by Polaris Pharmaceuticals Inc, H1 2020
Hyperuricemia - Pipeline by Shanghai Yingli Pharmaceutical Co Ltd, H1 2020
Hyperuricemia - Pipeline by Suzhou Sinovent Pharmaceuticals Co Ltd, H1 2020
Hyperuricemia - Pipeline by Teijin Pharma Ltd, H1 2020
Hyperuricemia - Pipeline by Xiuzheng Pharmaceutical Group Co Ltd, H1 2020
Hyperuricemia - Dormant Projects, H1 2020
Hyperuricemia - Discontinued Products, H1 2020

【掲載企業】

Allena Pharmaceuticals Inc
Arthrosi Therapeutics Inc
AstraZeneca Plc
FortuneRock (China) Ltd
Hinova Pharmaceuticals Inc
J-Pharma Co Ltd
Jiangsu Atom Bioscience and Pharmaceutical Co Ltd
Jiangsu Hengrui Medicine Co Ltd
Nippon Chemiphar Co Ltd
NuBioPharma LLC
PegBio Co Ltd
Polaris Pharmaceuticals Inc
Shanghai Yingli Pharmaceutical Co Ltd
Suzhou Sinovent Pharmaceuticals Co Ltd
Teijin Pharma Ltd
Xiuzheng Pharmaceutical Group Co Ltd

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[高尿酸血症治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆